Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price used: about $410 a share. Reports on the day after the Q3 print conflict: about $405 pre-market and $413 intraday on October 21 (Tradingpedia, Benzinga). I could not confirm an official close. Market capitalization is roughly $142 billion on 346.6 million shares, and enterprise value is about $135 billion after $6.8 billion of cash and investments and no debt. We have rarely seen a medical-device franchise this good. It sells a capital system once, then collects a toll on every procedure for a decade or more. It has no debt, converts earnings to cash, and keeps buying back stock. Revenue grew 22% in the September quarter on a $12 billion-plus base. We would own this business without hesitation at the right price. We do not think this is the right price. Four things lead us to Hold: The multiple.
Recent filings analysed: 8-K (2026-11-02), 10-Q (2026-10-21), 8-K (2026-10-20), 8-K (2026-07-27).
Stock screener · Superinvestor 13F holdings · Analyst sentiment